Centre Hospitalier Universitaire de Toulouse

Running trials

• Not yet recruiting

  A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

  NCT07335562· Phase 3· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Not yet recruiting

  Analysis of the Performance of PSMA Emission Tomography in Patients With Prostate Cancer Treated With HIFU

  NCT07766122· Phase 4· University Hospital, Toulouse· Source

• Not yet recruiting

  Safety and Efficacy of a STOPping Strategy Versus Classical Maintenance Dose of JAK Inhibitors in Deep Remission Patients With Ulcerative Colitis

  NCT07718529· Phase 4· Assistance Publique Hopitaux De Marseille· Source

• Not yet recruiting

  Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

  NCT07441408· Phase 3· Bristol-Myers Squibb· Source

• Not yet recruiting

  FILOCLL017 - NEVOTAL : Nemtabrutinib in addition to Venetoclax-Obinutuzumab in chronic lymphocytic leukemia (CLL) / small lymphocytic leukemia (SLL) patients with TP53 ALterations

  2026-525763-40-00· Phase 2· French Innovative Leukemia Organization (F.I.L.O.).· Source

• Not yet recruiting

  Effect of Botulinum Toxin on Resting Tremor of the Refractory Upper Limb in Parkinsonians

  NCT07822893· Phase 3· University Hospital, Toulouse· Source

• Not yet recruiting

  A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma

  NCT07612787· Phase 1/2· Centre Hospitalier Universitaire de Saint Etienne· Source

• Not yet recruiting

  Discontinuation or Continuation of SGLT-2 Inhibitors Before Cardiac Surgery

  NCT07766109· Phase 4· University Hospital, Toulouse· Source

• Not yet recruiting

  Prognostic and Predictive Factors in Childhood Soft Tissue Sarcomas

  NCT07924384· Institut Curie· Source

• Not yet recruiting

  FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial

  NCT07576452· Phase 4· University Hospital, Clermont-Ferrand· Source

• Recruiting

  A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease

  NCT07778667· Phase 3· Idorsia Pharmaceuticals Ltd.· Source

• Not yet recruiting

  A Phase 2 trial of AGMB-447 in participants with idiopathic pulmonary fibrosis

  2026-526404-71-00· Phase 2· Agomab Spain S.L.U.· Source

• Not yet recruiting

  Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance Dose

  NCT07700446· Phase 4· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Source

• Recruiting

  Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease

  NCT07781657· Phase 2· Hoffmann-La Roche· Source

• Not yet recruiting

  A Phase 2 study of VQ-101 in participants with Parkinson’s disease and GBA1 mutation

  2026-525848-15-00· Phase 2· Vanqua Bio Inc.· Source

• Recruiting

  Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease

  NCT07781644· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

  NCT07629583· Phase 1· Genentech, Inc.· Source

• Not yet recruiting

  To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

  NCT07116473· Phase 3· Eidos Therapeutics, a BridgeBio company· Source

• Not yet recruiting

  A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s Syndrome (ADCS) Including an Open-Label Extension for Long-Term Assessment. (EQUILIBRIUM-ADCS)

  2025-522648-42-01· Phase 2/3· Crinetics Pharmaceuticals Inc.· Source

• Not yet recruiting

  A trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.

  2026-525367-40-00· Phase 3· AstraZeneca AB· Source

• Recruiting

  Evaluation of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

  2025-523288-39-00· Phase 2· Mediar Therapeutics Inc.· Source

• Not yet recruiting

  Comparative Study of Two Vaccination Schedules for the Subunit Herpes Zoster Vaccine in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disease Patients Treated With Anti-CD20 Therapy: an Open-label Randomised Controlled Trial

  NCT07818356· Phase 4· University Hospital, Toulouse· Source

• Not yet recruiting

  Evaluation of the Efficacy and Safety of Bimekizumab (BZK) or Adalimumab (ADA) in the Treatment of Anterior Chest Wall Pain Associated With Active Axial Spondyloarthritis Refractory to NSAIDs With Hypothesis of Superiority of Bimekizumab

  NCT07836283· Phase 3· University Hospital, Rouen· Source

• Not yet recruiting

  Tenecteplase for the treatment of acute stroke in the late time window before inter-hospital transfer for thrombectomy: a randomized controlled trial

  2026-525280-40-00· Phase 3· Fondation A De Rothschild· Source

• Not yet recruiting

  Effect of GABAergic treatments on cortical plasticity and motor learning capacity in the subacute phase after stroke: a single-case experimental study (GABAPLAST)

  2026-526884-39-00· Phase 3· Centre Hospitalier Universitaire De Toulouse· Source

• Not yet recruiting

  Evaluate the superiority of Treatment with RAvulizumab vs plasma exchange during the first episode or a relapse In acute neuromyelitis optica (NMO) patients: a national, multicentric, randomised trial

  2026-526632-39-00· Phase 3· Les Hopitaux Universitaires De Strasbourg· Source

• Not yet recruiting

  Artificial Intelligence-based Parkinson's Disease Risk Assessment (AI-PRA) Study

  NCT07706829· Queen Mary University of London· Source

• Enrolling by invitation

  Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France

  NCT07729852· Phase 2· Alterity Therapeutics· Source

• Not yet recruiting

  ACetazolamide in Patients With Heart Failure, to Decrease Weight and relIEVE Symptoms.

  NCT07737964· Phase 3· University Hospital, Montpellier· Source

• Not yet recruiting

  Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors.

  NCT07853105· Phase 1/2· University Hospital, Strasbourg, France· Source

• Recruiting

  ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY

  NCT07545512· University Hospital, Clermont-Ferrand· Source

• Recruiting

  A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

  2026-526654-14-01· Phase 3· Janssen Cilag International· Source

• Recruiting

  Phase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)

  2026-525489-23-00· Phase 3· Amgen Inc.· Source

• Recruiting

  Evaluating Aganirsen Eye Drops to Reduce the Number of Aflibercept Injections in Wet Age-Related Macular Degeneration Patients.

  2026-526775-27-00· Phase 2· Laboratoires Kol· Source

• Recruiting

  A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

  NCT07465289· Phase 3· UCB Biopharma SRL· Source

• Recruiting

  Feasibility of the Application of a new Six-month Treatment for multidrug-resistant tuberculosis (MDR-TB) patients in France (FAST-MDR)

  2024-512763-32-00· Phase 3· Assistance Publique Hopitaux De Paris· Source

• Recruiting

  A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

  2025-525009-18-00· Phase 3· Incyte Corp.· Source

• Recruiting

  Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

  NCT07680790· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma.

  2025-523285-25-00· Phase 3· AstraZeneca AB· Source

• Not yet recruiting

  Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial

  NCT07721363· Phase 2· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  CUSHMAH - Benefit of steroidogenesis inhibitors in Mild Cushing syndrome (Mild Autonomous Cortisol Secretion): a randomized trial in patients with Primary Bilateral Macronodular Adrenocortical Hyperplasia

  2023-507010-27-00· Phase 3· Assistance Publique Hopitaux De Paris· Source

• Not yet recruiting

  Rollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Benefited from Continued Treatment.

  2026-526419-13-00· Phase 3· AstraZeneca AB· Source

• Not yet recruiting

  Impact of discontinuation of long-term macrolides in stable Non Cystic Fibrosis Bronchiectasis : a multicenter randomized controlled trial

  2025-521493-33-00· Phase 3· Centre Hospitalier Intercommunal Creteil· Source

• Not yet recruiting

  Evaluation of the Efficacy of Ischemic Preconditioning to Protect Against Acute Kidney Injury After Open Surgery for Juxtarenal Abdominal Aortic Aneurysm

  NCT07441564· University Hospital, Rouen· Source

• Not yet recruiting

  Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid Leukemia

  NCT07726576· Phase 1/2· University Hospital, Bordeaux· Source

• Not yet recruiting

  Short- and Mid-term Therapeutic, Prognostic, and Societal Impact of Implementing Intraoperative Assessment of Pulmonary Resection Quality for Lung Cancer

  NCT07828938· Fondation Hôpital Saint-Joseph· Source

• Not yet recruiting

  OBINUSS - A trial to evaluate a new drug in systemic sclerosis: obinutuzumab.

  2025-524003-68-00· Phase 2· Assistance Publique Hopitaux De Paris· Source

• Not yet recruiting

  Efficacy of FLUOXETINE in children with drug-resistant, complex and rare epilepsy (FLUOXEPIL)

  2024-519897-38-01· Phase 3· Centre Hospitalier Regional De Marseille· Source

• Not yet recruiting

  Prospective evaluation of response to treatment by analysis of measurable residual disease in younger adult patients (18-60 years) with acute myeloid leukemia (AML). The Backbone InterGroup (BIG)-2 umbrella trial from the Acute Leukemia French Intergroup (ALFA, FILO) - BIG2

  2026-525759-96-00· Phase 4· Centre Hospitalier Universitaire De Toulouse· Source

• Not yet recruiting

  Immunotherapy with a JAK1/JAK2 inhibitor (baricitinib) and an mTORC1 inhibitor (sirolimus), alone and in combination, for the control of HIV-1 replication after antiretroviral treatment interruption: a phase II multicenter, multi-arm, multi-stage, randomized, double-blind, placebo-controlled, adaptative trial

  NCT07081763· Phase 2· ANRS Maladies Infectieuses Emergentes· Source

Showing 50 of 595.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer32 recruiting
• Childhood cancers29 recruiting
• Multiple myeloma19 recruiting
• Stroke19 recruiting
• Crohn's disease15 recruiting
• Systemic sclerosis (scleroderma)15 recruiting
• Colorectal cancer14 recruiting
• Lupus (SLE)14 recruiting
• Alzheimer disease13 recruiting
• High blood pressure11 recruiting
• Parkinson disease11 recruiting
• Heart failure10 recruiting
• Acute lymphoblastic leukaemia9 recruiting
• Multiple sclerosis9 recruiting
• Rheumatoid arthritis9 recruiting
• Acute myeloid leukaemia8 recruiting
• Liver and biliary tract cancer8 recruiting
• COPD7 recruiting
• Epilepsy7 recruiting
• Ulcerative colitis7 recruiting
• Amyloidosis6 recruiting
• Chronic lymphocytic leukaemia6 recruiting
• Dermatomyositis and polymyositis (myositis)6 recruiting
• Fatty liver disease (MASLD/MASH)6 recruiting
• HIV6 recruiting
• Myasthenia gravis6 recruiting
• Neuroendocrine tumours6 recruiting
• Pancreatic cancer6 recruiting
• Sarcoma6 recruiting
• Kidney cancer5 recruiting
• Myelodysplastic syndromes5 recruiting
• Pulmonary arterial hypertension5 recruiting
• Type 1 diabetes5 recruiting
• ANCA-associated vasculitis4 recruiting
• Asthma4 recruiting
• Atrial fibrillation4 recruiting
• Bronchiectasis4 recruiting
• Chronic myeloid leukaemia4 recruiting
• Coronary artery disease4 recruiting
• Cystic fibrosis4 recruiting
• Gastric and oesophageal cancer4 recruiting
• Lewy body dementia4 recruiting
• Myocarditis4 recruiting
• Narcolepsy4 recruiting
• Type 2 diabetes4 recruiting
• Chronic kidney disease3 recruiting
• Hidradenitis suppurativa3 recruiting
• Idiopathic pulmonary fibrosis3 recruiting
• Liver cirrhosis3 recruiting
• Schizophrenia3 recruiting
• ALS (motor neurone disease)2 recruiting
• Ankylosing spondylitis2 recruiting
• Aortic stenosis2 recruiting
• Aplastic anaemia2 recruiting
• Atopic dermatitis (eczema)2 recruiting
• Bladder cancer2 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)2 recruiting
• Congenital heart disease2 recruiting
• Cushing's syndrome2 recruiting
• Cytomegalovirus infection2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Duchenne muscular dystrophy2 recruiting
• Immune thrombocytopenia (ITP)2 recruiting
• Macular degeneration2 recruiting
• Mesothelioma2 recruiting
• Multiple system atrophy2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Neuroblastoma2 recruiting
• Neuromyelitis optica (NMOSD)2 recruiting
• Obesity2 recruiting
• Osteoporosis2 recruiting
• Peripheral artery disease2 recruiting
• Prostate cancer2 recruiting
• Psoriasis2 recruiting
• Psoriatic arthritis2 recruiting
• Sarcoidosis2 recruiting
• Sickle cell disease2 recruiting
• Vitiligo2 recruiting
• Alopecia areata1 recruiting
• Aortic aneurysm1 recruiting
• Brain aneurysm1 recruiting
• Dystonia1 recruiting
• Endometrial cancer1 recruiting
• Endometriosis1 recruiting
• Fabry disease1 recruiting
• Follicular lymphoma1 recruiting
• Frontotemporal dementia1 recruiting
• Gout1 recruiting
• Haemophilia1 recruiting
• Hearing loss1 recruiting
• Hepatitis B1 recruiting
• Huntington's disease1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Sjögren's disease1 recruiting
• Spinal muscular atrophy1 recruiting
• Thyroid cancer1 recruiting
• Triple-negative breast cancer1 recruiting
• Tuberculosis1 recruiting
• Turner syndrome1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Recruiting

  A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

  2025-524711-36-00· Phase 3· Alkermes Inc.· Source

• Completed

  Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults with Advanced Colorectal Cancer.

  2025-523984-39-00· Phase 2· Gilead Sciences Inc.· Source

• Completed

  A study to investigate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn’s disease or ulcerative colitis

  NCT07222189· Phase 2· Sanofi-Aventis Recherche & Developpement· Source

• Recruiting

  Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

  NCT07286058· Phase 3· Takeda· Source

• Completed

  A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease

  2024-516966-12-00· Phase 2· Novartis Pharma AG· Source

• Terminated

  Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab

  NCT07061080· Phase 2· Grupo Espanol de Tumores Neuroendocrinos· Source

• Completed

  GSK4527226 Open-label Extension Study in Patients with Early Alzheimer's Disease.

  2025-521107-42-00· Phase 2· Glaxosmithkline Research & Development Limited· Source

• Recruiting

  Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)

  NCT07048262· Phase 2· CSL Behring· Source

• Completed

  A multicentre, randomised, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of BP1.4979 in adult patients with essential tremor

  2024-517987-46-00· Phase 2· Bioprojet Pharma· Source

• Recruiting

  AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

  NCT06991114· Phase 2· Artiva Biotherapeutics, Inc.· Source

• Completed

  A study to investigate efficacy and safety of SAR441566 in patients with ulcerative colitis

  NCT06867094· Phase 2· Sanofi-Aventis Recherche & Developpement· Source

• Completed

  A trial to learn how well benralizumab works and how safe it is when given in addition to standard asthma treatments in people with eosinophilic asthma

  2024-515162-13-00· Phase 3· AstraZeneca AB· Source

• Completed

  GUIDEX® Versus Launcher™ Guiding Catheter in Percutaneous Coronary Intervention (PCI) (GUIDEX_FR)

  NCT06009757· Tianjin Demax Medical Technology Co., Ltd· Source

• Completed

  A study to investigate efficacy and safety of SAR441566 in patients with Crohn's disease.

  NCT06637631· Phase 2· Sanofi-Aventis Recherche & Developpement· Source

• Completed

  Dose escalation of allogeneic Adipose derived Stroma/stem Cells for the treatment of Crohn’s fistula

  2024-511821-75-00· Phase 1/2· Centre Hospitalier Universitaire De Toulouse· Source

• Active, not recruiting

  A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

  NCT06671496· Phase 3· Takeda· Source

• Active, not recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

  NCT06744920· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases

  NCT06255028· Phase 1· Century Therapeutics, Inc.· Source

• Active, not recruiting

  A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

  NCT06593522· Phase 2· Amgen· Source

• Terminated

  A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)

  NCT06685835· Phase 2· Insmed Incorporated· Source

• Completed

  A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome

  NCT06312020· Phase 2· Horizon Therapeutics Ireland Designated Activity Company· Source

• Completed

  IFM 2020-01 (Isamyp) Efficacity assessment of isatuximab plus pomalidomide and dexamethasone in patients with AL amyloidosis who didn't reach at least a very good partial response with their previous treatment

  NCT05066607· Phase 2· Intergroupe Francophone Du Myelome· Source

• Completed

  Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHINE

  NCT06425159· Phase 2/3· Biohaven Therapeutics Ltd.· Source

• Completed

  A study to investigate the safety and pharmacological effect of a single intravenous infusion of GSK2857914 in male and female participants aged 18 to 75 with moderate to severe systemic lupus erythematosus

  NCT06413511· Phase 1· Glaxosmithkline Research & Development Limited· Source

• Completed

  Effect of Copper CU64 PSMA I&T scanning to detect potential disease spread to lymph nodes in men with newly diagnosed Prostate Cancer

  2024-512754-16-01· Phase 3· Curium US LLC· Source

• Completed

  A Study of TAK-861 in People With Narcolepsy Type 1

  NCT06505031· Phase 3· Takeda· Source

• Completed

  Phase 2 study to evaluate the efficacy and safety of GSK3915393 in participants with Idiopathic Pulmonary Fibrosis (IPF)

  NCT06317285· Phase 2· Glaxosmithkline Research & Development Limited· Source

• Completed

  A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe hidradenitis suppurativa

  2024-511363-28-00· Phase 3· MoonLake Immunotherapeutics AG· Source

• Active, not recruiting

  To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

  NCT06553027· Phase 3· Cerevance· Source

• Completed

  Study on the Long-Term Risk of Recurrence of Anoperineal Fistula in Crohn's Disease

  NCT06514092· University Hospital, Toulouse· Source

• Active, not recruiting

  RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms

  NCT06243458· Phase 2· GCP-Service International West GmbH· Source

• Completed

  Molecular Analysis of Thrombocytopenia and Cancer (MATAC): Investigating Antigenic Mimicry Between Platelets and Tumor Cells in Patients With Immune Thrombocytopenia (ITP) Associated With Cancer

  NCT06444477· University Hospital, Bordeaux· Source

• Completed

  Reperfusion with P2Y12 inhibitors in addition to mechanical thrombectomy for perfusion imaging selected acute stroke patients : a multicentric randomized controlled trial

  NCT04667078· Phase 4· Fondation A De Rothschild· Source

• Completed

  A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)

  2023-506185-31-00· Phase 2/3· Pliant Therapeutics Inc.· Source

• Completed

  A Study of TAK-861 for the Treatment of Narcolepsy Type 1

  NCT06470828· Phase 3· Takeda· Source

• Completed

  Effects of maintenance cabozantinib+BSC versus BSC in children and AYA with osteosarcoma. ( CabOSTar )

  NCT06341712· Phase 2· Ipsen Innovation· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

  NCT06425549· Phase 3· UCB Biopharma SRL· Source

• Completed

  A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight

  NCT06388187· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered in participants with PD-L1 ≥ 1% TC Stage IIB, IIIA, or select IIIB (T3N2 only) NSCLC following resection and adjuvant platinum-based chemotherapy

  2023-506696-10-00· Phase 3· F. Hoffmann-La Roche AG· Source

• Completed

  Performance and Hearing-related Outcomes in Adults Implanted With the CI622D Dexamethasone-eluting Cochlear Implant Compared to Those Implanted With a Standard Cochlear Implant (CI622)

  NCT06424262· Cochlear· Source

• Completed

  EPI-7386 in Combination with Enzalutamide versus Enzalutamide alone in Metastatic Castration-Resistant Prostate Cancer

  NCT05075577· Phase 1/2· Essa Pharma Inc.· Source

• Completed

  A Two-Part Study to Assess the Effectiveness, Safety, and Blood Levels of Repeat Doses of Inhaled ETD001 in People with Cystic Fibrosis

  2023-504092-25-00· Phase 2· Enterprise Therapeutics Limited· Source

• Completed

  A Phase IIb, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Subjects with Cystic Fibrosis Aged 18 Years or Older (CHOICES)

  2022-500410-26-01· Phase 2· University Medical Center Utrecht· Source

• Completed

  EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE

  NCT06079190· Phase 2· Glaxosmithkline Research & Development Limited· Source

• Completed

  Glenzocimab in Anterior stroke with Large Ischemic Core eligible for Endovascular therapy

  2023-509615-92-00· Phase 2· Hopital Fondation Adolphe De Rothschild· Source

• Completed

  Individualization of dosage regimens in obese patients: application to acyclovir

  2022-500879-31-00· Phase 1· Centre Hospitalier Universitaire De Toulouse· Source

• Completed

  A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis

  2023-504564-42-00· Phase 2· Anaptysbio Inc.· Source

• Completed

  A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

  NCT06131372· Phase 2· Novo Nordisk A/S· Source

• Completed

  A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

  NCT06323928· Phase 2· H. Lundbeck A/S· Source

• Active, not recruiting

  A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

  NCT06257875· Phase 2· AbbVie· Source

Showing 50 of 245.

Conditions

Diseases this institution publishes on or runs trials for.

• Multiple myeloma40 works · 35 trials
• Acute myeloid leukaemia33 works · 19 trials
• Amyloidosis18 works · 16 trials
• Spinal muscular atrophy11 works · 4 trials
• Immune thrombocytopenia (ITP)9 works · 6 trials
• Multiple system atrophy8 works · 8 trials
• Myelodysplastic syndromes8 works · 16 trials
• Brain aneurysm7 works · 1 trial
• Haemophilia6 works · 5 trials
• Neuromyelitis optica (NMOSD)5 works · 3 trials